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Objectives The aim of this study was to assess whether small arteries from visceral fat of obese patients show a reduced
nitric oxide (NO)-dependent relaxation, as compared with lean control subjects, focusing on the role of the pro-
inflammatory cytokine tumor necrosis factor (TNF)-.
Background Visceral obesity is characterized by endothelial dysfunction.
Methods Small arteries from 14 obese (body mass index 48.4  11 kg/m2) and 14 control subjects (body mass index
24.9  2 kg/m2), dissected after a visceral fat biopsy (laparoscopy), were evaluated on a pressurized micromyo-
graph. Endothelium-dependent relaxation was assessed by acetylcholine. The NO availability, superoxide produc-
tion, and inflammation were assessed by testing acetylcholine under the nitric oxide synthase (NOS) inhibitor
N-nitro-L-arginine methylester, tempol (superoxide scavenger), and infliximab (monoclonal anti–TNF- antibody),
respectively. The roles of nicotinamide adenine dinucleotide phosphate oxidase and inducible nitric oxide syn-
thase (iNOS) were assessed by their selective inhibitors apocynin and S-methylisothiourea (SMT), respectively.
Vascular superoxide generation (dihydroethidium staining) protein expression of TNF- and NOS isoforms (West-
ern Blot) and TNF- localization (immunohistochemistry) were assessed.
Results Vessels from obese patients displayed a blunted relaxation to acetylcholine and a reduced inhibitory effect of
N-nitro-L-arginine methylester. These alterations were normalized by tempol or infliximab while being partly
ameliorated by apocynin and SMT. Vascular superoxide generation was increased (p  0.01) in obese patients.
This condition was abrogated by both tempol and infliximab and partly (p  0.05 vs. control subjects) reduced
by apocynin or SMT. Enhanced TNF- and iNOS expression together with increased TNF- localization in the vas-
cular media were detected.
Conclusions Small arteries from visceral fat of obese patients are characterized by an increased TNF- production, which reduces
NO availability by promoting superoxide generation via nicotinamide adenine dinucleotide phosphate oxidase and
iNOS activation. (J Am Coll Cardiol 2011;58:238–47) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.050Endothelial dysfunction, secondary to an impaired nitric
oxide (NO) availability resulting from increased reactive
oxygen species (ROS) generation, is a common alteration of
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2010, accepted January 11, 2011.the major cardiovascular risk factors (1,2). Such alteration
represents a pathogenic mechanism determining atheroscle-
rotic disease and related cardiovascular events (3). Recently,
a key role played by low-grade vascular inflammation on
endothelial dysfunction and atherosclerosis emerged (4,5).
In particular, the pro-inflammatory cytokine tumor necrosis
See page 256
factor (TNF)- is involved in reducing vascular NO avail-
ability. This action is exerted both indirectly, by induction
of ROS generation via nicotinamide adenine dinucleotide
phosphate (NAD[P]H) oxidase or inducible nitric oxide
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July 12, 2011:238–47 TNF-, Obesity, and Endothelial Dysfunctionsynthase (iNOS) activation, and by direct inhibition of
endothelial nitric oxide synthase (eNOS) activity (4).
Obesity is a complex chronic disease associated with
increased cardiovascular mortality (6). Beyond the concom-
itance with cardiovascular risk factors—including hyperten-
sion, dyslipidemia, and diabetes mellitus—which greatly con-
tribute to accelerate vascular atherosclerosis, obesity is per se
responsible for direct detrimental effects on vasculature. In
particular, visceral obesity is characterized by reduced endothe-
lial function, an alteration documented in several different vascu-
lar districts (7–10). Over the past decade, obesity has been
independently associated with a condition of chronic inflamma-
tion secondary to an abnormal production of pro-inflammatory
mediators, including TNF-, which might negatively influ-
nce vascular reactivity (11,12). More recently, it was shown
hat local inflammation of perivascular fat might exert a
etrimental action on the vascular tone of adjacent small
essels in obese patients (13). These findings support a close
nteraction between obesity and inflammation and indicate
hat vasculature is a target of adipose tissue-derived inflam-
atory cytokines. However, whether low-grade inflammation can
e detected at the level of the vasculature from visceral fat is
till undetermined. In addition, the molecular mecha-
isms whereby vascular inflammation might affect vascu-
ar endothelial function in humans have not been fully
larified. Accordingly, the present study was designed to
ssess whether small resistance arteries, isolated from
isceral fat in patients with severe obesity, display endo-
helial dysfunction and the molecular mechanisms in-
olved in such alteration, with particular regard to the
utative pathogenic role of vascular TNF- on ROS
eneration and NO availability. The possible contribu-
ion of vascular NAD(P)H oxidase, iNOS, and xanthine
xidase on ROS generation was also assessed.
ethods
tudy population. The study population included 14 pa-
ients with severe abdominal obesity (age 39.8 10.2 years)
nd 14 nonobese control subjects (age 40.8  4.6 years).
bese patients were recruited among 220 consecutive pa-
ients referring to the Department of Endocrinology of our
niversity from January 2008 to January 2010 for screening
n view of laparoscopic bariatric surgery. The exclusion
riteria were: history or clinical evidence of hypertension
blood pressure 140/90 mm Hg); clinical or biochemical
vidence of thyroid, adrenal, or gonadal dysfunction; etha-
ol consumption (more than 60 g or one-half liter of
ine/day); hypercholesterolemia; diabetes mellitus; history
f congestive heart failure; cardiac and/or cerebrovascular
schemic disease; impaired renal function; smoking history;
r menopause. Patients taking cardiovascular or metabolic
rugs were also excluded. Control subjects were recruited
mong patients hospitalized into the Surgery Unit to undergo
aparoscopic surgery for cholecystectomy. Exclusion criteria iere the same as those adopted for
atients, and a body mass index
BMI) 30 kg/m2. The study
protocol was approved by the local
ethics committee. All participants
were aware of the nature and pur-
pose of the study and gave their
written consent.
Anthropometric and biochemical
measurements. Sitting blood
pressure (average of 3 measure-
ments) was measured with a
mercury sphygmomanometer, by
means of a standard cuff and a
large cuff in lean and obese indi-
viduals, respectively. Venous
blood samples were taken for
measurement of standard hema-
tology, TNF- (enzyme-linked
immunoadsorbent assay com-
mercial kit), and insulin (radio-
immunoassay). Insulin resistance
was estimated by the homeostasis
model assessment of insulin re-
sistance (HOMA-IR).
Preparation of small arteries
and functional experiments.
Small arteries (150 to 300 m,
pproximately 2 mm long) were
solated from visceral fat imme-
iately after biopsy sample pro-
urement, performed during
aparoscopic surgery, and mounted
n 2-glass microcannulae in a
ressurized myograph, as previ-
usly described (14,15). Endothelium-dependent and
ndothelium-independent relaxations were assessed by mea-
uring dilatory responses to cumulative concentrations of
cetylcholine (ACh) (1 nmol/l to 100 mol/l, Sigma
hemicals, St. Louis, Missouri) and sodium nitroprusside
0.01 to 100 mol/l, Sigma), respectively. Vessels were
re-contracted with noradrenaline (1 mol/l), whose con-
entration was chosen according to preliminary dose-
itration experiments, to establish the threshold concentra-
ion able to elicit similar contractions among the
xperimental groups (data not shown).
nfluence of NO availability and ROS production on
ndothelium-dependent relaxation. To evaluate NO
vailability and ROS production, curves to ACh were
onstructed before and after 30-min incubation with the
OS inhibitor N-nitro-L-arginine methylester (L-NAME)
(100 mol/l, Sigma) and the antioxidant and superoxide
ismutase mimetic tempol (1 mmol/l, Sigma) (16), respec-
ively. To assess whether ROS generation could influence
O availability, ACh was also infused under simultaneous
Abbreviations
and Acronyms
ACh  acetylcholine
BMI  body mass index
DAB  3,3
diaminobenzidine
tetra-hydrochloride
DHE  dihydroethidium
Emax  maximal
acetylcholine- and sodium
nitroprusside-induced
responses
eNOS  endothelial nitric
oxide synthase
HOMA-IR  homeostasis
model assessment of
insulin resistance
iNOS  inducible nitric
oxide synthase
L-NAME  N-nitro-L-
arginine methylester
NAD(P)H  nicotinamide
adenine dinucleotide
phosphate
NO  nitric oxide
PBS-T  Tween-20
phosphate-buffered saline
ROS  reactive oxygen
species
SMT  S-methylisothiourea
TNF  tumor necrosis
factor
WC  waist circumference
WHR  waist/hip rationcubation with L-NAME and tempol.
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TNF-, Obesity, and Endothelial Dysfunction July 12, 2011:238–47Involvement of TNF- in endothelium-dependent
elaxation. To ascertain the contribution of TNF- to
ndothelial dysfunction, in small vessels from obese patients
nd control subjects, a curve to ACh was constructed after
0-min incubation with the anti–TNF- monoclonal anti-
ody infliximab (100 mol/l, Schering-Plough [Merck],
Whitehouse Station, New Jersey). Previous in vitro studies
established that such infliximab concentration is able to
suppress the biological activity of TNF- (17). Acetylcho-
line was infused in arteries from obese patients under
simultaneous incubation with L-NAME and infliximab, to
assess the possibility that TNF- could affect NO
availability.
Influence of NAD(P)H oxidase and iNOS in endothelium-
dependent relaxation. To evaluate the influence of NAD(P)H
oxidase and iNOS on endothelial function, ACh was
tested on further sets of small arteries from obese
patients, after 30-min incubation with the NAD(P)H
oxidase inhibitor apocynin (10 mol/l, Fluka, Buchs, Switzer-
and) or the selective iNOS inhibitor S-methylisothiourea
SMT) (100 mol/l, Sigma). Finally, to assess whether
NAD(P)H oxidase or iNOS were involved in decreasing
NO availability, ACh was tested during simultaneous incu-
bation with L-NAME plus apocynin and/or SMT. Con-
centrations of apocynin and SMT were selected according
to previous studies reporting the concentrations able to
inhibit the respective enzymatic activities (15,18).
Detection of vascular superoxide anion generation. The
in situ production of superoxide anion was measured by
means of the fluorescent dye dihydroethidium (DHE)
(Sigma), as previously described (15). Three slides/segment
were analyzed simultaneously after incubation with tempol
(100 mol/l), infliximab (100 mol/l), apocynin (100 mol/l),
MT (100 mol/l), the xanthine oxidase inhibitor allopurinol
(100 mol/l), or Krebs solution at 37°C for 30 min. Krebs-N-
2-hydroxyethyl)-piperazine-N’-2-ethanesulfonic acid buffer
ontaining 2 mol/l DHE was then applied into each section
and evaluated under fluorescence microscopy. The percentage
of arterial wall area stained with the red signal was evaluated
with imaging software (McBiophotonics Image J, National
Institutes of Health, Bethesda, Maryland).
Western blot analysis of TNF-, iNOS, and eNOS.
Specimens of mesenteric arteries were homogenized in
radioimmunoprecipitation assay buffer with a polytron ho-
mogenizer and centrifuged at 20,000 rpm for 15 min at 4°C.
The resulting supernatants were separated from pellets and
stored at 20°C. Aliquots of 50 g of protein were
eparated by electrophoresis on 12% sodium dodecylsulfate-
olyacrylamide gel electrophoresis and transferred onto a
olyvinylidene fluoride membrane. The blots were then
locked for 2 h with 1% bovine serum albumin in Tween-20
hosphate-buffered saline (PBS-T) and incubated overnight
t room temperature with a primary antibody raised against
NOS, iNOS (BD Transduction Laboratories, San Jose,
alifornia), TNF- (Santa Cruz Biotechnology, SantaCruz, California), or beta-actin (Sigma-Aldrich, Milano, gItaly). After repeated washings with PBS-T, a peroxidase-
conjugated secondary antibody was added for 1 h at room
temperature. After repeated washings with PBS-T, immu-
noreactive bands were visualized by incubation with chemi-
luminescent reagents (Immobilon, Millipore, Massachu-
setts) and exposed to Kodak Image Station 440 (Eastman
Kodak Company, Rochester, New York) for signal and
densitometric image analysis. To ensure equal loading and
accuracy of changes in protein expression, protein levels
were normalized to beta-actin.
Immunostaining of TNF-. Tissue specimens were im-
mediately fixed in cold neutral 4% formaldehyde and then
paraffin-embedded. Eight-micrometer-thick sections were
microwaved; immunostained by rabbit anti–TNF- poly-
clonal antibodies (Abcam, Cambridge, Massachusetts); and
treated with biotinylated anti-rabbit immunoglobulins,
peroxidase-labeled streptavidin complex (Vector Laborato-
ries, Burlingame, California), and 3,3 diaminobenzidine
tetra-hydrochloride (DAB) (Dakopatts, Glostrup, Den-
mark), as previously reported (19). Negative controls were
obtained by substituting the primary antibody with pre-
immune rabbit serum. Endogenous peroxidases and
avidin-binding activity were assayed by incubating slides
with DAB alone or with streptavidin horseradish perox-
idase complex/DAB, respectively. The slides were exam-
ined under light microscope at 400 magnification
equipped with the digital camera DFC480 (Leica, Cam-
bridge, United Kingdom). In the whole artery section,
the percentage of immunoreactive tissue was evaluated on
representative wall microscopic fields with image analysis
software (McBiophotonics Image J) and normalized to
the total area examined.
Data analysis. Results are presented as mean  SEM and
analyzed by repeated measures analysis of variance, followed
by Student-Newman-Keuls test, or by unpaired Student t
test where appropriate. To highlight obesity-related factors
playing a major role as determinants of the impaired
NO-dependent relaxation, univariate and multivariate linear
regression analyses were performed between the inhibi-
tory effect of L-NAME on the maximal relaxant response
to ACh and BMI, waist circumference (WC), waist/hip
ratio (WHR), HOMA-IR, insulin, or TNF- plasma
evels. Finally, in the whole population, a linear correla-
ion between circulating TNF- levels and the extent of
ts vascular staining was assessed. A value of p  0.05 was
onsidered statistically significant. Maximal ACh- and
odium nitroprusside-induced responses (Emax) were cal-
ulated as maximal percentage increments of lumen
iameter.
esults
bese patients showed higher BMI, WC, and WHR values
ompared with control subjects, whereas blood pressure
alues, lipid profile, and plasma glucose were similar in both
roups. Plasma TNF-, insulin, HOMA-IR, and leptin
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July 12, 2011:238–47 TNF-, Obesity, and Endothelial Dysfunctionvalues were also higher in obese patients compared with
control subjects (Table 1).
Evaluation of NO availability and influence of ROS
production on endothelium-dependent relaxation. Small
arteries from obese patients showed significantly (p 
0.001) impaired relaxation responses to ACh, compared
with control subjects (Figs. 1A and 1B), whereas relaxations
to sodium nitroprusside were similar in obese (Emax: 94.5 
.1%) and control subjects (Emax: 95.1  1.4%). In arteries
rom control subjects, the relaxation to ACh was signifi-
antly blunted by L-NAME (Figs. 1A and 2), and tempol
did not affect the response to ACh or the inhibitory effect
of L-NAME on ACh-induced relaxation (Fig. 1A). By
contrast, in small vessels from obese patients, the inhib-
itory effect exerted by L-NAME on relaxation to ACh
was significantly lower compared with control subjects
(Figs. 1B and 2). In these vessels, tempol normalized the
endothelium-dependent relaxation and restored the in-
hibitory effect of L-NAME on ACh (Figs. 1B and 2).
nvolvement of TNF- in endothelium-dependent
elaxation. In the control group, relaxation to ACh (Emax:
5.5  1.8%) was not modified by infliximab (Emax: 95.1 
.4%). By contrast, in vessels from obese patients, inflix-
mab normalized the relaxation to ACh and also restored
he inhibitory effect of L-NAME on ACh (Fig. 1C). Of
ote, in the presence of infliximab, the blunting effect of
-NAME on ACh was similar to that elicited by tempol
nd no longer different from that recorded in control
ubjects (Fig. 2).
nfluence of NAD(P)H oxidase and iNOS on endothelium-
ependent relaxation. In arteries from obese patients,
pocynin greatly improved but did not normalize the relax-
tion to ACh and partly ameliorated the inhibition by
-NAME on ACh-induced responses (Emax ACh: 62.1 
.4%; AChL-NAME: 53.6  2.2%; AChapocynin:
8.7  0.5%; AChL-NAMEapocynin: 59.7  1.0%)
Clinical Characteristics andAnthropometri Values of Study PopulationsTable 1 Clinical Charac eristics andAnthropometric Values of Study Populations
Parameter Obese (n  14) Control Subjects (n  14)
Body mass index (kg/m2) 46.3 10* 24.5 2
Waist circumference (cm) 134.6 14.7* 92.0 4.6
Waist/hip 1.06 0.08* 0.93 0.03
Systolic blood pressure (mm Hg) 122.6 9.7 124.5 6.2
Diastolic blood pressure (mm Hg) 80.0 8.7 78.9 3.4
TNF- (pg/ml) 14.7 6.2* 8.6 6.5
Total cholesterol (mg/dl) 213 17 203 18
HDL cholesterol (mg/dl) 55 13 52 8
Triglycerides (mg/dl) 120 44 126 18
LDL cholesterol (mg/dl) 133 19 126 21
Fasting glucose (mg/dl) 99 14 89 6
Fasting insulin (U/ml) 13.6 4.2* 7.2 1.5
HOMA-IR 3.6 1.3* 1.6 0.4
Leptin (ng/ml) 22.3 5.2* 9.3 1.9
*p  0.05 versus control subjects.
HDL  high-density lipoprotein; HOMA-IR  homeostasis model assessment of insulin resis-
ance; LDL  low-density lipoprotein; TNF  tumor necrosis factor.Fig. 2). In these vessels SMT partly potentiated the
elaxation to ACh and the inhibitory effect of L-NAME on
ch (Emax ACh: 63.2  1.1%; AChL-NAME: 52.5 
1.3%; AChSMT: 80.2 0.8%; AChL-NAMESMT:
59.5  0.9%), similarly to results obtained with apocynin
(Fig. 2). When simultaneously infused, apocynin and SMT
normalized the relaxation to ACh (Emax: 96.7  2.1%) and
fully restored the inhibitory effect of L-NAME on ACh
(Fig. 2).
Determinants of NO availability in small arteries from
the whole study population. Univariate analysis showed a
Figure 1 Endothelium-Dependent Relaxation in
Small Arteries From Obese and Control Subjects
(A) Relaxations to acetylcholine (ACh) in control subjects  N-nitro-L-arginine
methylester (L-NAME), tempol, or both. (B) Relaxations to ACh in obese
patients  L-NAME, tempol, or both. (C) Relaxations to ACh in obese patients 
L-NAME, infliximab, or both. Each point is the mean of experiments  SEM.
*p  0.001; †p  0.05.significant inverse correlation between the inhibitory effect
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TNF-, Obesity, and Endothelial Dysfunction July 12, 2011:238–47of L-NAME on the maximal relaxation to ACh—taken as
an indirect index of NO availability—and BMI, WC,
WHR, HOMA-IR, insulin, or TNF- plasma levels
(Fig. 3). In multivariate analysis, obesity indexes were the
only independent predictors of reduced NO availability
(WC: r2  0.81; p  0.001; BMI: r2  0.54; p  0.01;
HR: r2  0.39; p  0.05). Of note, such analyses
nvolved the whole population, because of the linearity of
uch correlations, without a threshold value.
nalysis of vascular superoxide anion generation. In
mall vessels from obese patients, DHE analysis revealed a
ramatic increase in the superoxide anion production, com-
ared with control arteries (Fig. 4). The superoxide produc-
ion was abrogated by incubation with infliximab or tempol
nd partly decreased by apocynin or SMT. Incubation with
llopurinol was devoid of any effect (Fig. 4).
estern blot analysis of TNF-, iNOS, and eNOS. Small
vessels from obese patients showed a significantly higher
expression of TNF- as compared with control subjects.
Similarly, iNOS protein expression was significantly higher
in the obese group than control subjects. The eNOS
expression did not differ in the 2 study groups (Fig. 5).
Immunohistochemical analysis of TNF-. In control
arteries, a mild positive immunoreaction was detected
within the adventitia and outer smooth muscle cells. By
contrast, in vessels from obese patients, there was a
marked enhancement of TNF- immunostaining, mainly
ocalized within the smooth muscle compartment
Fig. 6). Vascular TNF- staining showed a significant
inear correlation with its circulating levels (r2  0.72;
Figure 2 Effects of L-NAME on Endothelium-Dependent Relaxat
Percentage inhibitory effect of L-NAME on maximal response to ACh  tempol, infl
resents the mean of experiments  SEM. *p  0.001 versus other groups; †p 
tions as in Figure 1. 0.01). piscussion
he first major novel finding of the present study consists in
he identification of mechanisms involved in endothelial
ysfunction, which affects small resistance arteries in the
isceral fat of obese patients. These vessels showed a blunted
ndothelium-dependent relaxation, together with a reduced
nhibitory effect of L-NAME on ACh-induced responses.
uch alterations were reversed by the superoxide scavenger
empol. In line with our functional findings, DHE analysis
evealed an increased vascular ROS generation, which was
brogated by tempol. The present results agree with—and
xtend to small resistance arteries from visceral fat—
revious demonstrations of endothelial dysfunction in obe-
ity (7–10) and provide the first demonstration that such
lterations depend on an increased intravascular superoxide
roduction, which reduces NO availability. To exclude
ossible confounders, we selected a young obese population,
ithout history of hypertension or evidence of impaired
lucose or lipid metabolism. Thus, vascular alterations, as
bserved in the present study, highlight a specific impact of
evere obesity per se on vascular reactivity. This is also
upported by our multivariate analysis, indicating obesity
ndexes as independent variables with a significant negative
mpact on reduced NO availability. However, our regression
nalysis was performed in a small group of patients, and a
onfirmation in a larger population is required.
ole of vascular TNF- on obesity-associated endothelial
dysfunction. Our obese patients showed higher plasma
levels of TNF- than lean control subjects, in line with a
Obese Patients and Control Subjects
, apocynin, S-methylisothiourea (SMT), or apocynin plus SMT. Each column rep-
versus control subjects, tempol, infliximab, and apocynin plus SMT. Abbrevia-ion in
iximab
0.05revious demonstration (11). Its role as a determinant of
m
b
c
l
t
243JACC Vol. 58, No. 3, 2011 Virdis et al.
July 12, 2011:238–47 TNF-, Obesity, and Endothelial Dysfunctionendothelial dysfunction was investigated by the anti–
TNF- monoclonal antibody infliximab. This compound
normalized the inhibitory effect of L-NAME on ACh-
induced relaxation. Likewise, DHE staining documented
that the increased superoxide generation was dramatically
reduced by infliximab. These findings provide the first
evidence that, in small arteries from the visceral adipose
tissue of obese patients, TNF- plays a major role in
aintaining a chronic condition of endothelial dysfunction
y stimulating intravascular superoxide generation. Ac-
ordingly, a significant up-regulation of TNF- protein
expression in vessels from obese patients was docu-
mented. Furthermore, immunohistochemistry indicated a
marked up-regulation of TNF- mainly in the media
ayer of these vessels. Finally, an inverse relationship be-
ween plasma TNF- levels and the inhibitory effect of
L-NAME on ACh emerged. Overall, these observations
support the concept that the vascular wall is the source of
Figure 3 Relationships Between the Effect of L-NAME on Endo
Inverse relationship between the percentage inhibitory effect of L-NAME on maxim
ratio (WHR), homeostasis model assessment of insulin resistance (HOMA-IR), insu
study. Abbreviations as in Figure 1.TNF- involved in endothelial dysfunction. However, thenormalization of vascular dysfunction by infliximab does not
necessarily exclude an involvement of additional inflamma-
tory mechanisms, accounting for vascular damage. As well,
the possibility that infliximab exerts vascular beneficial
effects by interacting with other unknown inflammatory
pathways cannot be excluded.
Previous studies in animal models of obesity and in
humans have demonstrated that rearrangements in the
visceral adipose tissue lead to an increased production of
pro-inflammatory cytokines, including TNF- (12,20). Re-
cent reports have investigated a possible link between
TNF- and obesity-related vascular dysfunction, because
the vasculature represents an important target for this
cytokine (21). Tesauro et al. (22) documented that inflix-
imab ameliorated peripheral vascular dysfunction during
hyperinsulinemia in obese patients by an antioxidant activ-
ity. More recently, a potential specific role of inflammation
from perivascular adipose tissue in the pathogenesis of
m-Dependent Relaxation and Obesity-Related Factors
xation to ACh and body mass index (BMI), waist circumference (WC), waist/hip
d tumor necrosis factor (TNF)- plasma values in the whole population of thetheliu
al rela
lin anvascular dysfunction has been investigated. It was observed
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TNF-, Obesity, and Endothelial Dysfunction July 12, 2011:238–47that, under healthy conditions, subcutaneous gluteal
perivascular fat exerts a protective activity on vasculature,
resulting from an anti-contractile property and a favorable
influence on NO availability (13) and that such beneficial
effects are lost in obese patients as a consequence of several
mechanisms, including an increased accumulation of
TNF- in the adipose tissue (13). These observations
nderscore the role of inflammation as an important pro-
oter of vascular dysfunction and support an important
echanism whereby, in obesity, the adipose tissue damages
he surrounding vasculature in a paracrine manner. Our
ndings add novelty to current knowledge through the
emonstration that the vasculature is not only a target but
lso a source of low-grade inflammation, which in turn—
ndependently of the perivascular adipose tissue—
ontributes to the pathogenesis of endothelial dysfunction
y activating ROS generation. However, our experimental
Figure 4 DHE Staining for Detection of Superoxide Production
Representative dihydroethidium (DHE) staining (top) and quantitative analysis of t
at baseline or after incubation with allopurinol, apocynin, S-methylisothiourea (SM
mean of 6 experiments  SEM. *p  0.001; †p  0.05.onditions did not allow assessment of whether the smallrteries and adipocytes, located within perivascular fat,
hould be regarded as independent and coexisting sites of
NF- generation or, by contrast, whether there is a
ierarchical relationship or mutual interplay between these 2
istricts. Although this issue needs future investigations, the
lose relationship between vascular TNF- staining and its
increased plasma levels supports the concept of obesity as a
generalized inflammatory condition. In this context, the role
of insulin deserves a comment. In healthy conditions,
insulin induces endothelium-dependent vasorelaxation
via NO stimulation (7,23). Thus, it is conceivable that
the condition of insulin resistance, which characterized
our obese patients, might have interfered with insulin
signal transduction, leading to an impaired NO genera-
tion. In such a scenario, TNF- promoted a further
exacerbation, resulting from its ability to reduce the
density of insulin receptor content at the level of endo-
signal (bottom) in small arteries from lean control subjects and obese patients
pol, or infliximab. Original magnification is 40. Each column represents thehe red
T), temthelial cells (24).
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July 12, 2011:238–47 TNF-, Obesity, and Endothelial DysfunctionPathway(s) involved in TNF-–induced vascular ROS
eneration. Toward this aim, we tested apocynin, because
f previous studies showing that TNF- is a relevant
stimulus for NAD(P)H oxidase induction (4). The role of
iNOS, another enzymatic pathway implicated in ROS
production, particularly under inflammatory conditions
(25,26), was investigated by its inhibitor SMT. In addition,
xanthine oxidase—as an additional endothelial source of
superoxide (27)—was assessed by allopurinol. Apocynin
partly restored the impaired endothelial function in the
obese group. Likewise, SMT increased but did not normal-
ize the NO availability in vessels from obese patients up to
values similar to those obtained by apocynin application.
The DHE staining showed, in line with these results, that
apocynin as well as SMT reduced only in part superoxide
generation in arteries from obese individuals. On the basis
of these findings, it is conceivable that both NAD(P)H
oxidase and iNOS are the 2 major enzymatic pathways that,
Figure 5 Western Blot Analysis of TNF-, iNOS, and eNOS in S
Representative blots and column graphs referring to the densitometric analysis of imm
*p  0.05. eNOS  endothelial nitric oxide synthase, iNOS  inducible nitric oxidonce simultaneously activated by TNF-, mediate vascularOS production in obesity, whereas xanthine oxidase does
ot seem to be implicated.
ascular NOS isoforms expression in obesity. Our
estern blot analysis revealed an up-regulation of iNOS in
rteries from the obese group, in concomitance with a
reserved eNOS protein expression. These findings, which
re being reported for the first time in human vessels, are in
pparent contrast with previous data showing an inhibiting
ffect of TNF- on eNOS expression (24,28,29). The
unmodified eNOS expression observed in our study suggests
that the reduced NO availability secondary to oxidant excess
represents a major mechanism accounting for endothelial
dysfunction in an obese population. This proposal agrees
with a previous demonstration of increased ROS generation
in obese patients, an excess reversed by weight loss (30). In
addition, we cannot exclude that iNOS—beyond its role as
a source of oxidative stress—might at least in part contribute
to NO generation, which in turn is rapidly inactivated by
rteries From Obese Patients and Control Subjects
active bands. Each column represents the mean of 6 experiments  SEM.
hase; TNF  tumor necrosis factor.mall A
unore
e syntROS.
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We have demonstrated that small resistance arteries, iso-
lated from the visceral adipose tissue of patients with severe
obesity, are characterized by a marked endothelial dysfunc-
Figure 6 Immunostaining for TNF- in Small Arteries
From Obese Patients and Control Subjects
The panels display representative images (original magnification 400), and
column graphs refer to the densitometric analysis of immunostained areas.
Specific tumor necrosis factor (TNF)- immunostaining is detected in the outer
layers of vessel wall in control samples. The TNF- expression is enhanced
and evident throughout the muscle layer in a vessel from obese patients
(arrow). *p  0.05.tion caused by a reduced NO availability. This alterationresults from an increased vascular production and biological
activity of TNF-, which promotes superoxide generation
via both NAD(P)H oxidase and iNOS activation.
We recognize that any extrapolation from the present to
other vascular districts requires caution, because the auto-
crine/paracrine functions of endothelium can vary, depend-
ing on the anatomical location of blood vessels. Neverthe-
less, these findings, while strengthening the concept that
obesity is an inflammatory condition, identify the small
vessels of visceral fat as important sources of low-grade
inflammation and oxidative stress that—together with the
perivascular adipose tissue (31)—might directly contribute
to the local development of insulin resistance, which char-
acterizes obese patients.
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